CODX vs. RVP, MDAI, DRIO, CTSO, DXR, ICAD, LNSR, NMTC, FEMY, and MODD
Should you be buying Co-Diagnostics stock or one of its competitors? The main competitors of Co-Diagnostics include Retractable Technologies (RVP), Spectral AI (MDAI), DarioHealth (DRIO), Cytosorbents (CTSO), Daxor (DXR), iCAD (ICAD), LENSAR (LNSR), NeuroOne Medical Technologies (NMTC), Femasys (FEMY), and Modular Medical (MODD). These companies are all part of the "surgical & medical instruments" industry.
Co-Diagnostics (NASDAQ:CODX) and Retractable Technologies (NYSE:RVP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership.
Co-Diagnostics currently has a consensus target price of $2.50, suggesting a potential upside of 125.23%. Given Co-Diagnostics' higher probable upside, equities analysts clearly believe Co-Diagnostics is more favorable than Retractable Technologies.
15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 7.6% of Retractable Technologies shares are held by institutional investors. 2.4% of Co-Diagnostics shares are held by insiders. Comparatively, 55.0% of Retractable Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Retractable Technologies has higher revenue and earnings than Co-Diagnostics. Retractable Technologies is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Co-Diagnostics has a beta of -0.67, suggesting that its stock price is 167% less volatile than the S&P 500. Comparatively, Retractable Technologies has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500.
In the previous week, Retractable Technologies had 1 more articles in the media than Co-Diagnostics. MarketBeat recorded 4 mentions for Retractable Technologies and 3 mentions for Co-Diagnostics. Retractable Technologies' average media sentiment score of 0.50 beat Co-Diagnostics' score of 0.30 indicating that Retractable Technologies is being referred to more favorably in the news media.
Co-Diagnostics received 273 more outperform votes than Retractable Technologies when rated by MarketBeat users. Likewise, 63.49% of users gave Co-Diagnostics an outperform vote while only 0.00% of users gave Retractable Technologies an outperform vote.
Retractable Technologies has a net margin of -26.86% compared to Co-Diagnostics' net margin of -518.69%. Retractable Technologies' return on equity of -10.84% beat Co-Diagnostics' return on equity.
Summary
Retractable Technologies beats Co-Diagnostics on 10 of the 16 factors compared between the two stocks.
Get Co-Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Co-Diagnostics Competitors List
Related Companies and Tools